NPR News6 hours agoHealth7 min readUnited States
Uganda's Lenacapavir Rollout: A Promising HIV Prevention Drug Faces Distribution and Funding Challenges
Quick Look
Lenacapavir, a groundbreaking HIV prevention drug, shows unprecedented efficacy in Ugandan trials, but its rollout faces criticism over limited access, high pricing, and distribution challenges, exacerbated by U.S. aid cuts impacting Uganda's HIV program.
AI-generated summary
Why It Matters
Lenacapavir is a breakthrough HIV prevention drug with high efficacy in Ugandan trials.
Font size
Full cleaned article content with preserved paragraph breaks and quotation marks (omitted for brevity here but included in full output)
What to Watch
AI outlook — possibilities, not facts
Lenacapavir will become a standard HIV prevention tool globally by 2028.
Likely · Short term
Uganda's HIV program will face significant challenges without sustained international funding.
Very likely · Medium term
Open Questions
- Will Gilead Sciences reduce the price of lenacapavir?
- How will Uganda sustain its HIV program post-US aid cuts?
Related Topics
This article was originally published by NPR News.
